OK given for testing higher dose of ITP treatment CID-103 in study
Casi Pharmaceuticals has been given the all-clear to start dosing a fifth group of patients in a clinical trial testing its treatment candidate CID-103…
Marisa Wexler MS, —
Articles by Marisa Wexler
FDA expands Vonvendi approval to cover more VWD patients
The U.S. Food and Drug Administration (FDA) has expanded its approval of Vonvendi (recombinant von Willebrand factor), a treatment for von Willebrand disease (VWD).
Combination therapy works to treat acquired TTP patients in India
Using both corticosteroids and plasma exchange therapy — each a standard treatment for acquired thrombotic thrombocytopenic purpura (TTP) — together was found to significantly…
TTP symptoms vary, but prevention helps control them: Study
The congenital form of thrombotic thrombocytopenic purpura (TTP) can look very different in one person than in another, but preventive treatment can help reduce…
Daratumumab injection therapy for cancer may help in hard-to-treat ITP
Daratumumab, an injection therapy approved to treat myeloma, may help to control immune thrombocytopenia (ITP) in individuals whose disease doesn’t respond well to available…
Ianalumab lengthens time patients can maintain safe platelet levels
A Phase 3 clinical trial testing ianalumab (VAY736) in combination with Promacta (eltrombopag) in people with primary immune thrombocytopenia (ITP) has met its main…
More Haemate-P use could mean big cost savings for Spain: Study
Increasing the use of Haemate-P to treat von Willebrand disease (VWD) could yield substantial savings for the healthcare system in Spain, a study found.
Dental procedures may lead to bleeding in VWD, hemophilia
People with von Willebrand disease (VWD) or hemophilia may experience bleeding complications after dental procedures, a new study highlights. Bleeding after such procedures, notably…
